Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-(3'-Methoxyphenyl) benzimidazole-4-carboxamide is a synthetic small molecule belonging to the phenylbenzimidazoles class. It is primarily recognized as an experimental compound with no current clinical or regulatory approval. The compound acts as an inhibitor of poly [ADP-ribose] polymerase 1 (PARP1), a key enzyme involved in DNA repair processes, and has demonstrated high binding affinity (Ki ~6 nM). While not approved for any medical indication, it serves as a valuable scaffold in medicinal chemistry research due to its potential anti-inflammatory, antimicrobial, antitumor, and antiviral activities. Its unique structure makes it useful for drug design and biological studies focused on PARP inhibition[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-(3'-methoxyphenyl) benzimidazole-4-carboxamide.